Limits...
Weight Changes in Patients with Differentiated Thyroid Carcinoma during Postoperative Long-Term Follow-up under Thyroid Stimulating Hormone Suppression.

Sohn SY, Joung JY, Cho YY, Park SM, Jin SM, Chung JH, Kim SW - Endocrinol Metab (Seoul) (2015)

Bottom Line: These gains among female DTC patients were also significant compared to age-matched control.Women in the THW group gained a significant amount of weight and BMI compared to baseline, while there was no increase in weight or BMI in the rhTSH group.Female DTC patients showed significant gains in weight and BMI during long-term follow-up after initial treatment.

View Article: PubMed Central - PubMed

Affiliation: Center for Thyroid Cancer, National Cancer Center, Goyang, Korea.

ABSTRACT

Background: There are limited data about whether patients who receive initial treatment for differentiated thyroid cancer (DTC) gain or lose weight during long-term follow-up under thyroid stimulating hormone (TSH) suppression. This study was aimed to evaluate whether DTC patients under TSH suppression experience long-term weight gain after initial treatment. We also examined the impact of the radioactive iodine ablation therapy (RAIT) preparation method on changes of weight, comparing thyroid hormone withdrawal (THW) and recombinant human TSH (rhTSH).

Methods: We retrospectively reviewed 700 DTC patients who underwent a total thyroidectomy followed by either RAIT and levothyroxine (T4) replacement or T4 replacement alone. The control group included 350 age-matched patients with benign thyroid nodules followed during same period. Anthropometric data were measured at baseline, 1 to 2 years, and 3 to 4 years after thyroidectomy. Comparisons were made between weight and body mass index (BMI) at baseline and follow-up.

Results: Significant gains in weight and BMI were observed 3 to 4 years after initial treatment for female DTC but not in male patients. These gains among female DTC patients were also significant compared to age-matched control. Women in the THW group gained a significant amount of weight and BMI compared to baseline, while there was no increase in weight or BMI in the rhTSH group. There were no changes in weight and BMI in men according to RAIT preparation methods.

Conclusion: Female DTC patients showed significant gains in weight and BMI during long-term follow-up after initial treatment. These changes were seen only in patients who underwent THW for RAIT.

No MeSH data available.


Related in: MedlinePlus

Weight gain by age group in female thyroid cancer patients who underwent thyroid hormone withdrawal before radioactive iodine ablation therapy. The values were evaluated with the Tukey post hoc test for group differences. aP<0.01 for group differences, age ≤40 years versus age 51 to 55 years and age >55 years.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4595360&req=5

Figure 1: Weight gain by age group in female thyroid cancer patients who underwent thyroid hormone withdrawal before radioactive iodine ablation therapy. The values were evaluated with the Tukey post hoc test for group differences. aP<0.01 for group differences, age ≤40 years versus age 51 to 55 years and age >55 years.

Mentions: Because age at surgery significantly affected weight gain, the female DTC patients were grouped according to age (≤40 years [n=69], 41 to 45 years [n=63], 46 to 50 years [n=51], 51 to 55 years [n=75], and ≥56 years [n=95]) at surgery and weight gain was compared at 3- to 4-year follow-up between age groups. Weight gain was greater in younger age group (Fig. 1). In the correlation analysis, there was a significant association between age at surgery and weight gain (r=-0.25, P<0.01). The younger the age at surgery, the greater the weight gain. In addition, TSH levels and weight gain were significantly correlated (r=0.14, P<0.01).


Weight Changes in Patients with Differentiated Thyroid Carcinoma during Postoperative Long-Term Follow-up under Thyroid Stimulating Hormone Suppression.

Sohn SY, Joung JY, Cho YY, Park SM, Jin SM, Chung JH, Kim SW - Endocrinol Metab (Seoul) (2015)

Weight gain by age group in female thyroid cancer patients who underwent thyroid hormone withdrawal before radioactive iodine ablation therapy. The values were evaluated with the Tukey post hoc test for group differences. aP<0.01 for group differences, age ≤40 years versus age 51 to 55 years and age >55 years.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4595360&req=5

Figure 1: Weight gain by age group in female thyroid cancer patients who underwent thyroid hormone withdrawal before radioactive iodine ablation therapy. The values were evaluated with the Tukey post hoc test for group differences. aP<0.01 for group differences, age ≤40 years versus age 51 to 55 years and age >55 years.
Mentions: Because age at surgery significantly affected weight gain, the female DTC patients were grouped according to age (≤40 years [n=69], 41 to 45 years [n=63], 46 to 50 years [n=51], 51 to 55 years [n=75], and ≥56 years [n=95]) at surgery and weight gain was compared at 3- to 4-year follow-up between age groups. Weight gain was greater in younger age group (Fig. 1). In the correlation analysis, there was a significant association between age at surgery and weight gain (r=-0.25, P<0.01). The younger the age at surgery, the greater the weight gain. In addition, TSH levels and weight gain were significantly correlated (r=0.14, P<0.01).

Bottom Line: These gains among female DTC patients were also significant compared to age-matched control.Women in the THW group gained a significant amount of weight and BMI compared to baseline, while there was no increase in weight or BMI in the rhTSH group.Female DTC patients showed significant gains in weight and BMI during long-term follow-up after initial treatment.

View Article: PubMed Central - PubMed

Affiliation: Center for Thyroid Cancer, National Cancer Center, Goyang, Korea.

ABSTRACT

Background: There are limited data about whether patients who receive initial treatment for differentiated thyroid cancer (DTC) gain or lose weight during long-term follow-up under thyroid stimulating hormone (TSH) suppression. This study was aimed to evaluate whether DTC patients under TSH suppression experience long-term weight gain after initial treatment. We also examined the impact of the radioactive iodine ablation therapy (RAIT) preparation method on changes of weight, comparing thyroid hormone withdrawal (THW) and recombinant human TSH (rhTSH).

Methods: We retrospectively reviewed 700 DTC patients who underwent a total thyroidectomy followed by either RAIT and levothyroxine (T4) replacement or T4 replacement alone. The control group included 350 age-matched patients with benign thyroid nodules followed during same period. Anthropometric data were measured at baseline, 1 to 2 years, and 3 to 4 years after thyroidectomy. Comparisons were made between weight and body mass index (BMI) at baseline and follow-up.

Results: Significant gains in weight and BMI were observed 3 to 4 years after initial treatment for female DTC but not in male patients. These gains among female DTC patients were also significant compared to age-matched control. Women in the THW group gained a significant amount of weight and BMI compared to baseline, while there was no increase in weight or BMI in the rhTSH group. There were no changes in weight and BMI in men according to RAIT preparation methods.

Conclusion: Female DTC patients showed significant gains in weight and BMI during long-term follow-up after initial treatment. These changes were seen only in patients who underwent THW for RAIT.

No MeSH data available.


Related in: MedlinePlus